NCT04666038 2025-04-20BRUIN CLL-321Eli Lilly and CompanyPhase 3 Active not recruiting238 enrolled 17 charts 1 FDA
NCT01796470 2020-06-02Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic MalignanciesGilead SciencesPhase 2 Terminated66 enrolled 14 charts